cert-20250331

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

FORM 10-Q

_________________________


(Mark One)
x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number: 001-39799

_________________________

Certara, Inc.

(Exact name of registrant as specified in its charter)

_________________________


Delaware			82-2180925

(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification Number)

4 Radnor Corporate Center

Suite 350

Radnor, Pennsylvania 19087

(Address of Principal Executive Offices)

(415) 237-8272

(Registrant’s telephone number)

_________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Exchange on which registered

Common stock, par value $0.01 per share

CERT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Table of Contents

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of May 1, 2025, the registrant had 162,233,828 shares of common stock, par value $0.01 per share, outstanding.

Table of Contents

Certara, Inc.

Unless otherwise indicated, references to the “Company,” “Certara,” “we,” “us,” and “our” refer to Certara, Inc. and its consolidated subsidiaries.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. All statements (other than statements of historical facts) in this Quarterly Report regarding the prospects of the industry and our prospects, plans, financial position and business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “should,” “expect,” “might,” “intend,” “will,” “estimate,” “anticipate,” “plan,” “seek,” “believe,” “predict,” “potential,” “continue,” “suggest,” “project,” “future,” “likely” or “target” or the negatives of these terms or variations of them or similar terminology. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance and are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The following factors are among those that may cause actual results to differ materially from the forward-looking statements:

•any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development;

•our ability to compete within our market;

•changes or delays in government regulation relating to the biopharmaceutical industry;

•trends in research and development (“R&D”) spending, the use of third parties by biopharmaceutical companies and a shift toward more R&D occurring at smaller biotechnology companies;

•consolidation within the biopharmaceutical industry;

•our ability to successfully increase our customer base, expand our relationships and the products and services we provide, and enter new markets;

•our ability to retain key personnel or recruit additional qualified personnel;

•risks related to the mischaracterization of our independent contractors;

•any delays or defects in our release of new or enhanced software or other biosimulation tools;

•issues relating to the use of artificial intelligence and machine learning in our products and services;

•failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by our existing customers;

•risks related to our contracts with government customers, including the ability of third parties to challenge our receipt of such contracts;

•our ability to sustain historic growth rates;

•any future acquisitions and our ability to successfully integrate such acquisitions;

•the accuracy of our addressable market estimates;

Table of Contents

•our ability to successfully operate a global business;

•adverse global economic conditions, including inflation, tariffs and/or trade disputes and fluctuating interest rates;

•our ability to comply with applicable anti-corruption, trade compliance and economic sanctions laws and regulations;

•risks related to litigation against us;

•the adequacy of our insurance coverage and our ability to obtain adequate insurance coverage in the future;

•our ability to perform our services in accordance with contractual requirements, regulatory standards and ethical considerations;

•the loss of more than one of our major customers;

•the ability or inability of our bookings to accurately predict our future revenue and our ability to realize the anticipated revenue reflected in our bookings;

•any disruption in the operations of the third-party providers who host our software solutions or any limitations on their capacity or interference with our use;

•our ability to reliably meet our data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet;

•any unauthorized access to or use of customer or other proprietary or confidential data or other breach of our cybersecurity measures;

•the occurrence of natural disasters, pandemics, epidemic diseases, and public health crises, which may result in delays or cancellations of customer contracts or decreased utilization by our employees;

•our ability to comply with the terms of any licenses governing our use of third-party open source software utilized in our software solutions;

•our ability to comply with applicable privacy and cybersecurity laws;

•our ability to adequately enforce or defend our ownership and use of our intellectual property and other proprietary rights;

•any allegations that we are infringing, misappropriating or otherwise violating a third party’s intellectual property rights;

•our ability to meet the obligations under our current or future indebtedness as they become due;

•any limitations on our ability to pursue our business strategies due to restrictions under our current or future indebtedness or inability to comply with any restrictions under such indebtedness;

•any impairment of goodwill or other intangible assets;

•the accuracy of our estimates and judgments relating to our critical accounting policies and any changes in financial reporting standards or interpretations;

•any inability to design, implement, and maintain effective internal controls when required by law, or inability to timely remediate internal controls that are deemed ineffective; and

•the other factors described elsewhere in this Quarterly Report, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (“2024 Annual Report”), and in the other documents and reports we file with the Securities and Exchange Commission (the “SEC”).

Table of Contents

You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements in this Quarterly Report are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. There are important factors, including those described in in this Quarterly Report, in the section titled “Risk Factors” in our most recent Annual Report, and in our subsequent SEC filings, which could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements.

The forward-looking statements made in this Quarterly Report relate only to events as of the date on which the statements are made. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations.

Channels for Disclosure of Information

Investors and others should note that we may announce material information to the public through filings with the SEC, our Investors Relations website (https://ir.certara.com), press releases, public conference calls and public webcasts. We use these channels to communicate with the public about the Company, our products, our services and other matters. We have used, and intend to continue to use, our Investor Relations website and our corporate website located at www.certara.com as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. We encourage our investors, the media and others to review the information disclosed through these channels as such information could be deemed to be material information. The information on or available through such channels, including on our website, is not incorporated by reference in this Quarterly Report and shall not be deemed to be incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. This list of disclosure channels may be updated from time to time.

Table of Contents

CERTARA, INC. AND SUBSIDIARIES

FORM 10-Q

TABLE OF CONTENTS


Item		Page

	PART I – FINANCIAL INFORMATION

1.	Financial Statements (Unaudited)	7

	Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 202 4	7

	Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three months ended March 31, 2025 and 2024	8

	Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2025 and 2024	9

	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024	10

	Notes to Condensed Consolidated Financial Statements	11

2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	31

3.	Quantitative and Qualitative Disclosures About Market Risk	46

4.	Controls and Procedures	46

	PART II – OTHER INFORMATION

1.	Legal Proceedings	48

1A.	Risk Factors	48

2.	Unregistered Sales of Equity Securities and Use of Proceeds	48

3.	Defaults Upon Senior Securities	48

4.	Mine Safety Disclosures	48

5.	Other Information	48

6.	Exhibits	49

SIGNATURES		50

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements


CERTARA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)


(IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA)	MARCH 31, 2025		DECEMBER 31, 2024
Assets
Current assets:
Cash and cash equivalents	$	179,086	$	179,183
Accounts receivable, net of allowance for credit losses of $2,244 and $2,164, respectively	93,438		102,189
Prepaid expenses and other current assets	27,651		29,480
Total current assets	300,175		310,852
Other assets:
Property and equipment, net	1,914		2,167
Operating lease right-of-use assets	13,205		13,841
Goodwill	764,338		757,038
Intangible assets, net of accumulated amortization of $358,459 and $338,809, respectively	475,405		485,214
Deferred income taxes	3,961		3,961
Other long-term assets	2,013		2,031
Total assets	$	1,561,011	$	1,575,104
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	5,068	$	3,502
Accrued expenses	23,440		56,451
Current portion of deferred revenue	72,035		77,829
Current portion of long-term debt	3,000		3,000
Other current liabilities	4,536		5,306
Total current liabilities	108,079		146,088
Long-term liabilities:
Deferred revenue, net of current portion	1,277		1,049
Deferred income taxes	39,142		40,421
Operating lease liabilities, net of current portion	9,834		11,166
Long-term debt, net of current portion and debt discount	291,798		292,425
Other long-term liabilities	26,602		25,299
Total liabilities	476,732		516,448
Commitments and contingencies
Stockholders' equity
Preferred shares, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	—		—
Common shares, $0.01 par value, 600,000,000 shares authorized, 162,426,898 and 161,958,810 shares issued, 161,475,707 and 161,009,112 shares outstanding as of March 31, 2025 and December 31, 2024, respectively	1,625		1,620
Additional paid-in capital	1,229,660		1,216,925
Accumulated deficit	(123,538)		(128,281)
Accumulated other comprehensive loss	(5,268)		(13,424)
Treasury stock at cost, 951,191 and 949,698 shares at March 31, 2025 and December 31, 2024, respectively	(18,200)		(18,184)
Total stockholders' equity	1,084,279		1,058,656
Total liabilities and stockholders' equity	$	1,561,011	$	1,575,104

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents


CERTARA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)


	THREE MONTHS ENDED MARCH 31,
(IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA)	2025		2024
Revenues	$	106,004	$	96,654
Cost of revenues	41,521		39,255
Operating expenses:
Sales and marketing	12,717		10,687
Research and development	10,522		11,995
General and administrative	19,654		22,979
Intangible asset amortization	13,094		12,593
Depreciation and amortization expense	873		432
Total operating expenses	56,860		58,686
Income (loss) from operations	7,623		(1,287)
Other income (expenses):
Interest expense	(4,806)		(5,751)
Net other income	1,725		1,604
Total other expenses	(3,081)		(4,147)
Income (loss) before income taxes	4,542		(5,434)
Benefit for income taxes	(201)		(751)
Net income (loss)	4,743		(4,683)
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax of $(110) and $60, respectively	8,742		(7)
Change in fair value from interest rate swap, net of tax of $(208) and $186 respectively	(586)		564
Total other comprehensive income	8,156		557
Comprehensive income (loss)	$	12,899	$	(4,126)

Net income (loss) per share attributable to common stockholders:
Basic	$	0.03	$	(0.03)
Diluted	$	0.03	$	(0.03)
Weighted average common shares outstanding:
Basic	160,996,258		159,524,270
Diluted	161,350,292		159,524,270

The accompanying notes are an integral part of the condensed consolidated financial statements.


CERTARA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)


(IN THOUSANDS, EXCEPT SHARE DATA)	COMMON STOCK			ADDITIONAL PAID-IN CAPITAL		ACCUMULATED DEFICIT		ACCUMULATED OTHER COMPREHENSIVE LOSS		TREASURY STOCK			TOTAL STOCKHOLDERS' EQUITY
	SHARES	AMOUNT								SHARES	AMOUNT
Balance as of December 31, 2024	161,958,810	$	1,620	$	1,216,925	$	(128,281)	$	(13,424)	(949,698)	$	(18,184)	$	1,058,656
Equity-based compensation expense, net of forfeiture	—	—		7,070		—		—		—	—		7,070
Common stock withheld for tax liabilities	—	—		—		—		—		(1,493)	(16)		(16)
Common shares issued for employee share-based compensation	12,744	—		—		—		—		—	—		—
Common shares issued for contingent consideration	455,344	5		5,665		—		—		—	—		5,670

Change in fair value from interest rate swap, net of tax	—	—		—		—		(586)		—	—		(586)
Net income	—	—		—		4,743		—		—	—		4,743
Foreign currency translation adjustment, net of tax	—	—		—		—		8,742		—	—		8,742
Balance as of March 31, 2025	162,426,898	$	1,625	$	1,229,660	$	(123,538)	$	(5,268)	(951,191)	$	(18,200)	$	1,084,279

Balance as of December 31, 2023	160,284,901	$	1,603	$	1,178,461	$	(116,230)	$	(7,593)	(436,615)	$	(9,401)	$	1,046,840
Equity-based compensation expense, net of forfeiture	—	—		9,073		—		—		—	—		9,073
Common stock withheld for tax liabilities	—	—		—		—		—		(60,177)	(1,136)		(1,136)
Common shares issued for employee share-based compensation	188,293	2		(2)		—		—		—	—		—
Common shares issued for contingent consideration	214,692	2		3,705		—		—		—	—		3,707
Change in fair value from interest rate swap, net of tax	—	—		—		—		564		—	—		564
Net loss	—	—		—		(4,683)		—		—	—		(4,683)
Foreign currency translation adjustment, net of tax	—	—		—		—		(7)		—	—		(7)
Balance as of March 31, 2024	160,687,886	$	1,607	$	1,191,237	$	(120,913)	$	(7,036)	(496,792)	$	(10,537)	$	1,054,358

The accompanying notes are an integral part of the condensed consolidated financial statements.


CERTARA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)


	THREE MONTHS ENDED MARCH 31,
(IN THOUSANDS)	2025		2024
Cash flows from operating activities:
Net income (loss)	$	4,743	$	(4,683)
Adjustments to reconcile net income (loss ) to net cash provided by operating activities:
Depreciation and amortization of property and equipment	873		432
Amortization of intangible assets	17,741		15,996
Amortization of debt issuance costs	144		380
Provision for credit losses	322		59
Equity-based compensation expense	7,070		9,073
Change in fair value of contingent considerations	(179)		2,878
Goodwill impairment
Deferred income taxes	10,502		(4,829)
Changes in assets and liabilities:
Accounts receivable	8,736		3,635
Prepaid expenses and other assets	1,807		(578)
Accounts payable, accrued expenses, and other liabilities	(27,783)		(14,825)
Deferred revenues	(5,448)		(3,271)
Other operating activities, net	(1,176)		29
Net cash provided by operating activities	17,352		4,296
Cash flows from investing activities:
Capital expenditures	(600)		(619)
Capitalized software development costs	(5,174)		(2,959)


Net cash used in investing activities	(5,774)		(3,578)
Cash flows from financing activities:
Payments on long-term debt	(750)		(755)
Payments for business acquisition related contingent consideration	(13,230)		(8,649)
Payment of taxes on shares withheld for employee taxes	(16)		(943)
Net cash used in financing activities	(13,996)		(10,347)
Effect of foreign exchange rate on cash and cash equivalents	2,321		(546)
Net decrease in cash and cash equivalents, and restricted cash	(97)		(10,175)
Cash and cash equivalents at beginning of period	179,183		234,951
Cash and cash equivalents at end of period	$	179,086	$	224,776
Supplemental disclosures of cash flow information
Cash paid for interest	$	4,648	$	5,395
Cash paid for taxes	$	688	$	3,640
Supplemental schedule of noncash investing and financing activities
Stock issuance or establish liabilities related to business acquisition contingent consideration	$	5,670	$	3,707

The accompanying notes are an integral part of the condensed consolidated financial statements.

CERTARA, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

(UNAUDITED)

1. Description of Business

Certara, Inc. and its wholly-owned subsidiaries (together, the “Company”) deliver software products and technology-driven services to customers to efficiently carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. The Company is a global leader in biosimulation, and the Company’s biosimulation software and technology-driven services help optimize, streamline, or even waive certain clinical trials to accelerate programs, reduce costs, and increase the probability of success. The Company’s regulatory science and market access software and services are underpinned by technologies such as regulatory submissions software, natural language processing, and Bayesian analytics. When combined, these solutions allow the Company to offer customers end-to-end support across the entire product life cycle.

The Company has operations in the United States, Australia, Canada, China, Egypt, France, Germany, Hungary, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom.

2. Summary of Significant Accounting Policies

There have been no changes other than what is discussed herein to the Company’s significant accounting policies as compared to the significant accounting policies described in Note 2. “Summary of Significant Accounting Policies” to the Company’s audited consolidated financial statements included in the Company’s 2024 Annual Report. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes as of and for the year ended December 31, 2024.

(a) Basis of Presentation and Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other estimates, assumptions used in the allocation of the transaction price to separate performance obligations, estimates towards the measure of progress of completion on fixed-price service contracts, the determination of fair values and useful lives of long-lived assets as well as intangible assets, goodwill, allowance for credit losses for accounts receivable, recoverability of deferred tax assets, recognition of deferred revenue, valuation of interest rate swaps, determination of fair value of equity-based awards, measurement of fair value of contingent consideration, and assumptions used in testing for impairment of long-lived assets. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements.

(b) Unaudited Interim Financial Statements

The accompanying condensed consolidated balance sheet as of March 31, 2025, the condensed consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2025 and

2024, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2025 and 2024, the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024, and the related interim disclosures are unaudited.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of the Company’s operations and cash flows for interim periods in accordance with U.S. GAAP. Certain amounts reported in prior periods have been reclassified to conform with the current presentation. Interim period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s 2024 audited consolidated financial statements and notes thereto. The information as of December 31, 2024 in the Company’s condensed consolidated balance sheet included herein is derived from the Company’s audited consolidated financial statements included in the Company’s 2024 Annual Report.

In December 2023, the Financial Accounting Standards Board “FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The ASU requires disclosure of specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold and further disaggregation of income taxes paid for individually significant jurisdictions. The ASU will be effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the disclosures within our consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. This ASU seeks to improve of the disclosures about the types of expenses, including employee compensation, depreciation, and amortization, and costs incurred related to inventory and manufacturing activities. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. In January 2025, the FASB also issued ASU 2025-01 to clarify the effective date. The Company is currently evaluating the impact of the ASU on the disclosures within its consolidated financial statements.

(d) Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

(e) Fair Value Measurements

The Company follows FASB Accounting Standards Codification (“ASC”) 820-10, “Fair Value Measurements” (“ASC 820-10”), which defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and requires certain disclosures about fair value measurements.

ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the most advantageous market for the asset or liability in an orderly transaction. Fair value measurement is based on a hierarchy of observable or unobservable inputs. The standard describes three levels of inputs that may be used to measure fair value.

Level 1 — Inputs to the valuation methodology are quoted prices available in active markets for identical securities as of the reporting date;

Level 2 — Inputs to the valuation methodology are other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk etc. as of the reporting date, and the fair value can be determined through the use of models or other valuation methodologies; and

Level 3 — Inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity of the securities and the reporting entity makes estimates and assumptions relating to the pricing of the securities including assumptions regarding risk.

If the inputs used to measure fair value fall at different levels of the fair value hierarchy, the hierarchy is based on the lowest level of input that is significant to the fair value measurement. For the acquisitions noted in Note 4, the fair value measurement methods used to estimate the fair value of the assets acquired and liabilities assumed at the acquisition dates utilized a number of significant unobservable inputs of Level 3 assu

SEC Form 10-Q filed by Certara Inc.